Physician profile
David D Markoff
NPI 1750376240
$1,770.66
in general payments reported to CMS, 2019-2025
18 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $45.00 · 2021: $97.40 · 2022: $189 · 2023: $538 · 2024: $191 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $420.31 | 2022-2025 | Tecnis Iol, Veritas Vision System, Tecnis Simplicity |
| Alcon Vision LLC | $362.72 | 2022-2025 | Hydrus Microstent, Tryptyr, Simbrinza |
| Allergan, INC. | $249.36 | 2019-2022 | |
| New World Medical,INC. | $207.47 | 2019-2023 | |
| Sight Sciences, INC. | $121.64 | 2022-2025 | Omni Surgical System |
| Rxsight INC | $63.53 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $50.02 | 2023 | Vyzulta, Miebo |
| Glaukos Corporation | $45.63 | 2022-2025 | Idosetr |
| Horizon Therapeutics Plc | $44.13 | 2023 | Tepezza |
| Dompe US, INC. | $41.44 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $27.00 | 2025 | Xdemvy |
| Abbvie INC. | $24.81 | 2025 | |
| Biotissue Holdings INC. | $23.31 | 2023 | |
| Amgen INC. | $20.92 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.66 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $17.37 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.31 | 2019 | |
| Ivantis, INC | $16.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Markoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.